Blue Water Vaccines, Inc. (BWV), a biopharmaceutical company, had an abysmal Thursday as it closed the day at $10.17 after plummeting 82.76% during the day. However, the stock has bounced back to an extent in the premarket, as it has surged by 38.64% and is trading at $14.10 at the time of the writing.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Publication in Journal
The latest release from BWV was regarding the publication in a Journal. On 22nd March, the company announced that its licensing partner “Cincinnati Children’s Hospital Medical Center” had published a research paper. The paper was titled “Bioengineered pseudovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicity” and was published in “Nano Research”. The paper supports the company’s exploration concerning the utilization of shell and protrusion platforms in the development of vaccine candidates.
Biopharma Sector Having a Hard Time
Market observers are of the view that the biopharma sector has been having a dismal sentiment since 2022 began. The inflationary pressure is making it hard for the biopharma industry to maintain the same level of performance as it had continued during the last few years. Furthermore, there are fears that the ongoing war between Russia and Ukraine would also impact the economy, causing deterioration in the performance of the biopharma sector.
BWV; Best IPO of 2022
BWV has been pronounced across the market as the best-performing IPO of 2022. The primary reason for that is the stock rose to about 540% from its IPO price, i.e. $9, before nose-diving during Thursday’s regular trading session. The exceptional performance of the stock came at a time when the IPOs were having a dismal period.
Looking ahead, signs are that BWV stock would continue to have this mercurial trend in near future. However, if recent past performance is any standard to go by, BWV looks set to have an outstanding time in the long run. Therefore, investors should opt for longer-term investment in the stock to achieve solid returns.